UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000043543
Receipt number R000049725
Scientific Title Human intervention trial on the effect of long-term ingestion of dry powdered ecklonia stolonifera from Nishinoshima-chou on the reduction of nasal and eye discomfort
Date of disclosure of the study information 2021/03/08
Last modified on 2021/09/06 09:10:36

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Human intervention trial on the effect of long-term ingestion of dry powdered ecklonia stolonifera from Nishinoshima-chou on the reduction of nasal and eye discomfort

Acronym

Human intervention trial on the effect of long-term ingestion of dry powdered ecklonia stolonifera from Nishinoshima-chou on the reduction of nasal and eye discomfort

Scientific Title

Human intervention trial on the effect of long-term ingestion of dry powdered ecklonia stolonifera from Nishinoshima-chou on the reduction of nasal and eye discomfort

Scientific Title:Acronym

Human intervention trial on the effect of long-term ingestion of dry powdered ecklonia stolonifera from Nishinoshima-chou on the reduction of nasal and eye discomfort

Region

Japan


Condition

Condition

Healthy Adults

Classification by specialty

Not applicable

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Examine the effects of capsules containing dried powder of ecklonia stolonifera from Nishinoshimachou on nasal and eye discomfort when taken continuously for four weeks by Japanese men and women aged 20 to 64 years.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

QOL Questionnaire
(Using the japan rhinoconjunctivitis quality of life questionnaire, JACQLQ ver.1)

Key secondary outcomes

Evaluation of subjective nasal and eye symptoms (by recording in daily diary)
Blood tests (6 specific IgE items, non-specific IgE, CRP)
s-IgA in saliva (concentration, secretion rate)


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Ingest 250 mg of dextrin (1 tablet) daily for 4 weeks

Interventions/Control_2

Ingest 340 mg of capsules containing dried powdered ecklonia tolonifera from Nishinoshimachou (1 tablet) daily for 4 weeks

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

1.Persons who received a sufficient explanation of the purpose and contents of the exam, have the capacity to consent, applied with free will with sufficient understanding, and agreed to participate with a written document.

2.Healthy Japanese who are 20 years old or more and under 65 years old.

3.Persons who have nasal or eye discomfort due to pollen or other causes but are not receiving otolaryngology consultation or medication.

Key exclusion criteria

1.Persons who have chronic illness, receiving medication, have a serious disease history (diabetes, liver disease, kidney disease, heart disease, respiratory disease, endocrine disease, etc.)

2.Persons who have allergy to the test food (ecklonia stolonifera), shrimp and crab.

3.Persons who regularly take test food (ecklonia stolonifera).

4.Persons who regularly take seaweed, foods containing seaweed or supplements.

5.Persons who are seeing or planning to see an otorhinolaryngologist.

6.Persons who have been diagnosed with acute rhinitis, sinusitis, or hypertrophic rhinitis.

7.Persons who have been diagnosed with bronchial asthma.

8.Persons who have severe anemia, alcoholism, or other mental disorders.

9.Persons who have a smoking habit.

10.Persons who regularly use medicines, specified health foods, or health foods that may affect nasal or eye discomfort.

11.Persons who may change their lifestyle during the study period (e.g., working at night, traveling for long periods of time).

12.Persons who plan to take new health foods or supplements during the study period.

13.Persons who have participated in other studies during the month prior to the start of the study, or persons who plan to participate in other studies after consenting to this study.

14.Persons who have been judged ineligible by the study supervising physician or principal investigator.

15.Persons who are breast-feeding, pregnant, or who plan or wish to become pregnant during the study period.

Target sample size

60


Research contact person

Name of lead principal investigator

1st name Eriko
Middle name
Last name Watanabe

Organization

Healthcare Systems Co., Ltd.

Division name

Research and Development Department

Zip code

105-0004

Address

Nisshin Tatemono Shinbashi Bld. 7F, 4-6-15 Shinbashi, Minato-ku, Tokyo, JAPAN

TEL

03-6809-2722

Email

watanabe@hc-sys.jp


Public contact

Name of contact person

1st name Eriko
Middle name
Last name Watanabe

Organization

Healthcare Systems Co., Ltd.

Division name

Research and Development Department

Zip code

105-0004

Address

Nisshin Tatemono Shinbashi Bld. 7F, 4-6-15 Shinbashi, Minato-ku, Tokyo, JAPAN

TEL

03-6809-2722

Homepage URL


Email

watanabe@hc-sys.jp


Sponsor or person

Institute

Healthcare Systems Co., Ltd

Institute

Department

Personal name



Funding Source

Organization

TAKAKI Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)

Nishinoshimachou


IRB Contact (For public release)

Organization

The Ethics Committee of Healthcare Systems Co., Ltd.

Address

Nisshin Tatemono Shinbashi Bld. 7F, 4-6-15 Shinbashi, Minato-ku, Tokyo, JAPAN

Tel

03-6809-2722

Email

soumu@hc-sys.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 03 Month 08 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

60

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2021 Year 03 Month 07 Day

Date of IRB

2021 Year 03 Month 07 Day

Anticipated trial start date

2021 Year 03 Month 08 Day

Last follow-up date

2021 Year 07 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 03 Month 07 Day

Last modified on

2021 Year 09 Month 06 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049725


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name